News Archives - Page 12 of 14 - Renalytix

Renalytix uses cookies to improve your experience. We respect your privacy and are committed to protecting your personal data. Read Privacy Notice.

Investors KidneyIntelX

RenalytixAI Announces Pricing of Global Offering and Approval to List on the Nasdaq Global Market

NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (“ RenalytixAI ” or the “ Company ”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs,

By renalytixprod|2023-09-25T10:58:11+00:0007.16.20|News|0 Comments

RenalytixAI Announces Launch of Global Offering and Application to List on the Nasdaq Global Market

NEW YORK, July 13, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announced the commencement of an

By renalytixprod|2023-09-07T10:58:23+00:0007.13.20|News|0 Comments

RenalytixAI Announces Partnership with America’s Choice Provider Network for Coverage Expansion

Expands access and coverage of KidneyIntelX™ into key regions for commercial growth NEW YORK, July 8, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved

By renalytixprod|2023-08-03T10:56:26+00:0007.08.20|News|0 Comments

RenalytixAI Announces KidneyIntelX Validation Study Accepted for Publication in American Society of Nephrology Journal Kidney360

NEW YORK, July 1, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announced that results of a

By renalytixprod|2023-07-21T10:58:11+00:0007.01.20|News|0 Comments

RenalytixAI Announces Partnership with the University of Michigan to Extend KidneyIntelX™ Use to Broad CKD Populations and Data Sharing Agreement with a Top Ten Global Pharmaceutical Company

NEW YORK, June 30, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announced a partnership with

By renalytixprod|2023-07-07T10:57:35+00:0006.30.20|News|0 Comments

RenalytixAI Announces Public Filing of Registration Statement with SEC for a Proposed Nasdaq Dual-listing and Global Offering

NEW YORK, June 25, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announced the public filing of a

By renalytixprod|2023-07-03T10:58:39+00:0006.25.20|News|0 Comments

KidneyIntelX™ Receives New York State Approval to Commence Commercial Testing

NEW YORK, June 12, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announced that it has received a

By renalytixprod|2023-06-29T22:01:57+00:0006.12.20|News|0 Comments

Renalytix AI Announces Proposed Dual-listing on Nasdaq

NEW YORK, May 18, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has

By renalytixprod|2023-06-15T10:57:25+00:0005.18.20|News|0 Comments

RenalytixAI Utah Commercial Laboratory Facility Achieves ISO 13485 Certification

NEW YORK, April 27, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announced today that it has received ISO 13485:2016 certification for its development and commercial laboratory

By renalytixprod|2023-06-09T10:57:22+00:0004.27.20|News|0 Comments

KidneyIntelX™ to Predict Major Adverse Kidney Events in COVID-19 Patients

NEW YORK, April 20, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that the KidneyIntelX™ platform will be used by investigators from the Icahn School of Medicine

By renalytixprod|2023-06-05T10:57:48+00:0004.20.20|News|0 Comments

Previous 111213 Next

Latest News, Blogs & More

kidneyintelX.dkd

FOLLOW US

© 2024 Renalytix

Renalytix Clinical Laboratories:
New York City, NY

Client Service: 1-888-203-2725
Copyright © 2024